{"id":53634,"date":"2023-09-20T09:49:00","date_gmt":"2023-09-20T09:49:00","guid":{"rendered":"https:\/\/medsname.com\/urotel-xl\/"},"modified":"2026-04-30T10:25:11","modified_gmt":"2026-04-30T10:25:11","slug":"urotel-xl","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/urotel-xl\/","title":{"rendered":"Urotel XL"},"content":{"rendered":"

<\/p>\n

\n

\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Urotel XL<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 tolterodine tartrate extended-release 4 mg ER<\/strong> made by Sun Pharma. It is used for overactive bladder (OAB) symptoms — urgency, frequency and urge incontinence. Take exactly as directed by your clinician \u2014 do not adjust the dose yourself.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\ud83d\udd12 \u039a\u03c1\u03c5\u03c0\u03c4\u03bf\u03b3\u03c1\u03b1\u03c6\u03b7\u03bc\u03ad\u03bd\u03b7 \u039f\u03bb\u03bf\u03ba\u03bb\u03ae\u03c1\u03c9\u03c3\u03b7 \u0391\u03b3\u03bf\u03c1\u03ac\u03c2<\/strong> \u00b7 \ud83d\udcb3 \u0395\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03bf\u03c2 \u0395\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae\u03c2<\/strong> \u00b7 \ud83d\ude9a \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u0391\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/strong> \u00b7 \u2b50 4.9\/5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2<\/strong><\/div>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03c4\u03af\u03b4\u03b1 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ad\u03bd\u03b1 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/strong>. Orders ship in plain, unbranded packaging from our fulfilment partners and are covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a>. We have served 1,400+ verified customers<\/strong> with a 4.9\/5 average rating<\/strong> across more than 600 medications.<\/p>\n

What Urotel XL is and how it works<\/h2>\n

Urotel XL contains tolterodine tartrate<\/strong> in an extended-release<\/strong> formulation, taken once daily. Tolterodine is a competitive muscarinic receptor antagonist that targets bladder muscarinic receptors with somewhat greater functional effect than salivary-gland receptors, giving a slightly better dry-mouth profile than oxybutynin (especially in the ER formulation).<\/p>\n

It is licensed for OAB with symptoms of urinary frequency, urgency and urge incontinence<\/strong>. The ER capsule provides smoother plasma levels than the older immediate-release tablet and reduces the typical side effects (especially dry mouth) by ~30%.<\/p>\n

Dose and how to take it<\/h2>\n\n\n\n\n\n\n\n
Patient group<\/th>\nRecommended dose<\/th>\n<\/tr>\n<\/thead>\n
Adults with OAB<\/td>\n4 mg once daily<\/strong><\/td>\n<\/tr>\n
Reduced to 2 mg once daily if<\/td>\nSevere hepatic \/ renal impairment (eGFR <30); concurrent strong CYP3A4 inhibitor; CYP2D6 poor metaboliser with side effects<\/td>\n<\/tr>\n
\u03a3\u03bf\u03b2\u03b1\u03c1\u03ae \u03b7\u03c0\u03b1\u03c4\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 (Child-Pugh C)<\/td>\n\u0391\u03c0\u03bf\u03c6\u03cd\u03b3\u03b5\u03c4\u03b5<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Swallow the capsule whole<\/strong>, with or without food, at the same time each day. Do not crush, chew or open the capsule. Improvement begins in 1–2 weeks; full benefit in 4–8 weeks. If no useful effect at 8 weeks, review.<\/p>\n

\n

⚠ Slug-vs-molecule warning<\/strong><\/p>\n

The brand name Urotel XL<\/strong> contains the syllable “urotel” that some buyers associate with alpha-blockers (Urief \/ Urotel) for BPH. Do \u03b4\u03b5\u03bd<\/strong> assume this is an alpha-blocker. Urotel XL is an antimuscarinic for OAB<\/strong> — a different class with different indications. If you have BPH-related obstruction, you need an alpha-blocker (silodosin, alfuzosin, tamsulosin), not tolterodine.<\/p>\n<\/div>\n

\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Side effect<\/th>\n\u03a3\u03c5\u03c7\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1<\/th>\n\u03a3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2<\/th>\n<\/tr>\n<\/thead>\n
\u039e\u03b7\u03c1\u03bf\u03c3\u03c4\u03bf\u03bc\u03af\u03b1<\/td>\nVery common (~25% IR \/ ~17% ER)<\/td>\nHydration, sugar-free gum<\/td>\n<\/tr>\n
\u0394\u03c5\u03c3\u03ba\u03bf\u03b9\u03bb\u03b9\u03cc\u03c4\u03b7\u03c4\u03b1<\/td>\nCommon (~7%)<\/td>\nFibre, fluids; bulk laxative if needed<\/td>\n<\/tr>\n
\u039e\u03b7\u03c1\u03bf\u03c6\u03b8\u03b1\u03bb\u03bc\u03af\u03b1<\/td>\n\u03a3\u03c5\u03c7\u03bd\u03ac<\/td>\nLubricant drops<\/td>\n<\/tr>\n
\u039a\u03b5\u03c6\u03b1\u03bb\u03b1\u03bb\u03b3\u03af\u03b1<\/td>\n\u03a3\u03c5\u03c7\u03bd\u03ac<\/td>\nUsually settles in 2 weeks<\/td>\n<\/tr>\n
\u0394\u03c5\u03c3\u03c0\u03b5\u03c8\u03af\u03b1<\/td>\n\u03a3\u03c5\u03c7\u03bd\u03ac<\/td>\n\u03a0\u03ac\u03c1\u03c4\u03b5 \u03bc\u03b5 \u03c6\u03b1\u03b3\u03b7\u03c4\u03cc<\/td>\n<\/tr>\n
Drowsiness, blurred vision<\/td>\n\u03a3\u03c5\u03c7\u03bd\u03ac<\/td>\nAvoid driving until adjusted<\/td>\n<\/tr>\n
Urinary retention<\/td>\n\u0391\u03c3\u03c5\u03bd\u03ae\u03b8\u03b9\u03c3\u03c4\u03b5\u03c2<\/td>\nStop and review<\/td>\n<\/tr>\n
QT prolongation (high doses)<\/td>\n\u03a3\u03c0\u03ac\u03bd\u03b9\u03b5\u03c2<\/td>\nAvoid combining with other QT-prolongers<\/td>\n<\/tr>\n
Acute angle-closure glaucoma<\/td>\n\u03a3\u03c0\u03ac\u03bd\u03b9\u03b5\u03c2<\/td>\nSame-day ophthalmology if eye pain<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n\n\n\n\n\n\n\n\n\n
Combination<\/th>\n\u0391\u03c0\u03bf\u03c4\u03ad\u03bb\u03b5\u03c3\u03bc\u03b1<\/th>\nAction<\/th>\n<\/tr>\n<\/thead>\n
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin)<\/td>\nTolterodine levels rise — risk of QT effects<\/td>\nReduce to 2 mg\/day<\/td>\n<\/tr>\n
Strong CYP2D6 inhibitors (fluoxetine, paroxetine)<\/td>\nTolterodine accumulates<\/td>\nWatch for side effects<\/td>\n<\/tr>\n
Other anticholinergics (oxybutynin, TCAs, sedating antihistamines)<\/td>\nAdditive burden<\/td>\nAvoid stacking<\/td>\n<\/tr>\n
QT-prolonging drugs (sotalol, amiodarone, methadone, ondansetron, citalopram > 20 mg)<\/td>\nAdditive QT risk<\/td>\nAvoid combination<\/td>\n<\/tr>\n
\u0392\u03b1\u03c1\u03c6\u03b1\u03c1\u03af\u03bd\u03b7<\/td>\nNo clinically significant interaction<\/td>\nStandard INR monitoring<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who should not take Urotel XL<\/h2>\n